Table 1 Baseline demographics (intent-to-treat population)a
PF-05280014 (n = 114) | Trastuzumab-EU (n = 112) | Total (N = 226) | |
|---|---|---|---|
Age, mean (±SD), years | 54.0 (11.9) | 51.2 (12.7) | 52.6 (12.3) |
Race, n (%) | |||
White | 112 (98.2) | 109 (97.3) | 221 (97.8) |
Black | 1 (0.9) | 0 | 1 (0.4) |
Asian | 1 (0.9) | 3 (2.7) | 4 (1.8) |
Ethnicity, n (%) | |||
Hispanic/Latino | 0 | 1 (0.9) | 1 (0.4) |
Not Hispanic/Latino | 114 (100.0) | 111 (99.1) | 225 (99.6) |
Mean body mass index (±SD), kg/m2 | 28.2 (5.9) | 27.7 (6.2) | 27.9 (6.1) |
Primary tumour size, n (%) | |||
<5 cm | 89 (78.1) | 89 (79.5) | 178 (78.8) |
≥5 cm | 25 (21.9) | 23 (20.5) | 48 (21.2) |
Oestrogen receptor status, n (%) | |||
Positive | 58 (50.9) | 54 (48.2) | 112 (49.6) |
Negative | 56 (49.1) | 58 (51.8) | 114 (50.4) |
Progesterone receptor status, n (%) | |||
Positive | 41 (36.0) | 40 (35.7) | 81 (35.8) |
Negative | 73 (64.0) | 72 (64.3) | 145 (64.2) |
